CHICAGO , Oct. 28, 2024 /PRNewswire/ -- Cardiosense , a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation's 2024 annual Transcatheter Cardiovascular Therapeutics® (TCT®) scientific symposium. The presentation highlighted interim performance and demographic data on the first 500 patients enrolled in its SEISMIC-HF I clinical study to develop a novel non-invasive method for cardiac pressure estimation.
"Over a million patients with heart failure are hospitalized in the U.S. each year, accounting for more than three-quarters of an estimated $30 billion in direct medical costs.
Numerous studies have shown that remote hemodynamic-guided management of patients using implanted sensors is effective at decreasing the risk of hospitalizations and mortality, and yet only a fraction of patients can use this technology," said Amit Gupta , Co-founder and CEO of Cardiosense. "This new data marks an important milestone in our development of a non-invasive heart failure management platform aimed at democratizing specialty care to expand access to a much larger population of heart failure patients." The data were presented by Anjan Tibrewala , M.
D. of Northwestern Medicine's Bluhm Cardiovascular Institute as a moderated abstract presentation titled, Study Design and Interim Results of the Non-Invasive SEISMocardiogram In Cardiovascular Monitoring for .
